Myriad presents tumor BRACAnalysis CDx study at ESMO

(Myriad Genetics, Inc.) Data presented at the European Society for Medical Oncology annual meeting show that Myriad's Tumor BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. The results show that the Tumor BRACAnalysis CDx test identified 28.3 percent of women with either germline or somatic BRCA1/2 mutations. In contrast, blood germline testing only identified the 19.6 percent of patien...